Parkinson’s Disease affects over 8.5 million people globally and is often diagnosed too late - when significant neurological damage has already occurred. Current monitoring relies on infrequent clinical visits and subjective reporting, leaving a critical gap in timely intervention, treatment personalization, and quality-of-life tracking.

Koios Care addresses these challenges with a passive, AI-powered platform that continuously monitors disease progression and Health-related Quality of Life (HrQoL) through digital biomarkers, using off-the-shelf wearables. Initially applied to Parkinson’s but built with the flexibility to support other neurodegenerative conditions in the future, the platform analyzes multimodal sensor data to deliver clinically validated, real-time insights - enabling earlier intervention, symptom reduction, treatment personalization, and precision adjustment.

With a device agnostic, cost-efficient approach and strong clinical reliability, Koios Care empowers patients, physicians, and pharma with actionable data - reshaping long-term neurological care and enabling the shift toward personalized, data-driven disease management at scale.